

References

I-35

1. Sandborn W, Feagan B, Marano C, et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. *Gastroenterology*. 2013.
2. Ueda N, Tsukamoto H, Mitoma H, et al. The cytotoxic effects of certolizumab pegol and golimumab mediated by Transmembrane Tumor Necrosis Factor α . *Inflammatory Bowel Diseases*. 2013;19:1224-1231.
3. Sandborn W, Feagan B, Marano C, et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. *Gastroenterology*. 2014; 146:85-95.
4. Kavanaugh A, McInnes I, Mease P, et al. Clinical efficacy, radiographic and safety findings through 2 years of golimumab treatment in patients with active psoriatic arthritis: Results from a long-term extension of the randomised, placebo-controlled GO-REVEAL study. *Annals of the Rheumatic Disease*. 2013;72(11):1777–1785.
5. Kirkham B, Wasko M, Hsia E, et al. Effects of golimumab, an anti-tumour necrosis factor- α human monoclonal antibody, on lipids and markers of inflammation. *Annals of the Rheumatic Disease*. 2014;73(1):161–169.
6. Terdiman J, Gruss C, Heidelbaugh J. American Gastroenterological Association Institute Guideline on the use of Thiopurines, Methotrexate, and Anti-TNF- α Biologic Drugs for the induction and maintenance of remission in inflammatory Crohn's Disease. *Gastroenterology*. 2013;145:1459-1463.
7. Simponi Aria® (golimumab) prescribing information. Horsham, PA: Janssen Biotech Inc. 2015.
8. Deochar A, Branu J, Inman R, et al. Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 5-year results of the GO-RAISE study. *Annals of the Rheumatic Diseases*. 2015;74:757–761.
9. Löwenberg M, Boer N, Hoentjen F. Golimumab for the treatment of ulcerative colitis. *Clinical and Experimental Gastroenterology*. 2014;7:53-59.
10. Ward M, Deodhar A, Akl E, et al. American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. *Arthritis Rheumatology*. 2015.
11. Sandborn W, Feagan B, Marano C, et al. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. *Gastroenterology*. 2014;146:96–109.
12. Sandborn W, Feagan B, Marano C, et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. *Gastroenterology*. 2014;146:85–95.
13. Smolen, Kay J, Doyle M, et al. 2015. Golimumab in patients with active rheumatoid arthritis after treatment with tumor necrosis factor inhibitors: findings with up to five years of treatment in the multicenter, randomized, double-blind, placebo-controlled, phase 3 GO-AFTER study. *Arthritis Research & Therapy*. 2015;17:14.

14. Ramiro S, Smolen J, Landewé, et al. Pharmacological treatment of psoriatic arthritis: A systematic literature review for the 2015 update of the European League against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis. *Annals of the Rheumatic Diseases*. 2015;0:1–9.
15. Tursi A, Allegretta L, Buccianti N, et al. Effectiveness and safety of golimumab in treating outpatient ulcerative colitis: a real-life prospective, multicentre, observational study in primary inflammatory bowel diseases centers. *J Gastrointestin Liver Dis*. 2017;239-244.
16. Svedbom A, Storck C, Kachroo S, et al. Persistence with golimumab in immune-mediated rheumatic diseases: a systematic review of real-world evidence in rheumatoid arthritis, axial spondyloarthritis, and psoriatic arthritis. *Patient Preference and Adherence*. 2017;719–729.
17. MICROMEDEX®SOLUTIONS Compendia. 2017. Golimumab.
18. Clinical Pharmacology Compendia. [database online]. Tampa FL: Gold Standard, Inc. Golimumab.